No Data
No Data
Buy Rating Affirmed for VYNE Therapeutics on Promising Clinical Advancements and Strategic Pipeline Progression
Analysts' Top Healthcare Picks: VYNE Therapeutics (VYNE), TriSalus Life Sciences (TLSI)
VYNE Therapeutics | 10-Q: Quarterly report
Buy Rating for VYNE Therapeutics on Strong Financial Footing and Promising Clinical Pipeline
VYNE Therapeutics Q1 EPS $(0.15) Beats $(0.24) Estimate, Sales $98.00K Miss $100.00K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.24) by 37.5 percent. This is a 89.86 percent increase over losses of $(1
Express News | Vyne Reports First Quarter 2024 Financial Results and Provides Business Update
No Data